Drugs / Setrusumab
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 27 trials | ||||||
| Phase 2 | NCT05312697 | Apr → Jul 2022 | osteogenesis imperfecta | Ultragenyx Pharmaceutical Inc | Terminated | No outcome recorded |
| Phase 2 | NCT03216486 | Oct 2017 → Nov 2018 | osteogenesis imperfecta | Ultragenyx Pharmaceutical Inc | Withdrawn | No outcome recorded |
| Phase 2 | NCT03118570 | Sep 2017 → Oct 2019 | osteogenesis imperfecta type 1, osteogenesis imperfecta type 3, osteogenesis imperfecta type 4 | Ultragenyx Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 2 | NCT01806610 | Aug 2013 → Apr 2014 | end stage renal failure | Ultragenyx Pharmaceutical Inc | Withdrawn | No outcome recorded |
| Phase 2 | NCT01406548 | Jul 2011 → Oct 2013 | osteoporosis | Ultragenyx Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 2 | NCT01406977 | Jul 2011 → Sep 2012 | hypophosphatasia | Ultragenyx Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 2 | NCT01417091 | Jun 2011 → Dec 2012 | osteogenesis imperfecta | Ultragenyx Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05125809 | Feb 2022 → Oct 2025 overdue | osteogenesis imperfecta | Ultragenyx Pharmaceutical Inc | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06636071 | Oct 2024 → Jan 2027 expected | osteogenesis imperfecta | Ultragenyx Pharmaceutical Inc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05768854 | Jun 2023 → Oct 2025 overdue | osteogenesis imperfecta | Ultragenyx Pharmaceutical Inc | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Setrusumab | “BPS804 IV Setrusumab given in escalating doses from 5mg/Kg to 20mg/Kg” NCT01406977 ↗ |
| Known as | BPS804 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03216486 ↗ |
| Known as | MOR05813 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297918 ↗ |
| Action | Inhibit | “Setrusumab, a neutralizing antibody to sclerostin” PMID 39012717 ↗ Sep 20241“Sclerostin inhibitor” CHEMBL4297918 ↗ |
| Modality | Monoclonal antibody | “BPS804, a fully human anti-sclerostin monoclonal antibody” PMID 28436937 ↗ Apr 2017 |
| Route | Intravenous | “received 3 ascending intravenous doses of 5, 10, and 20 mg/kg BPS804” PMID 28436937 ↗ Apr 2017 |
| Target | SOST | “Sclerostin inhibitor” CHEMBL4297918 ↗ |